About ocugen inc - OCGN
Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.
OCGN At a Glance
Ocugen, Inc.
11 Great Valley Parkway
Malvern, Pennsylvania 19355
| Phone | 1-484-328-4701 | Revenue | 4.41M | |
| Industry | Pharmaceuticals: Major | Net Income | -67,846,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 8.829% | |
| Fiscal Year-end | 12 / 2026 | Employees | 116 | |
| View SEC Filings |
OCGN Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 91.826 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -6.936 |
| Enterprise Value to Sales | 95.128 |
| Total Debt to Enterprise Value | 0.079 |
OCGN Efficiency
| Revenue/Employee | 38,043.103 |
| Income Per Employee | -584,879.31 |
| Receivables Turnover | N/A |
| Total Asset Turnover | 0.069 |
OCGN Liquidity
| Current Ratio | 1.056 |
| Quick Ratio | 1.056 |
| Cash Ratio | 0.806 |
OCGN Profitability
| Gross Margin | 45.864 |
| Operating Margin | -1,425.697 |
| Pretax Margin | -1,537.412 |
| Net Margin | -1,537.412 |
| Return on Assets | -106.315 |
| Return on Equity | -776.892 |
| Return on Total Capital | -323.415 |
| Return on Invested Capital | -171.415 |
OCGN Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | 157.994 |
| Total Debt to Total Assets | 74.836 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 147.945 |